CMV and DTaP vaccines
The vaccines committee will discuss ways to demonstrate attenuation of chimeric strains of cytomegaloviral candidate vaccines to support proceeding into clinical trials on the morning of Nov. 4. In the afternoon, the committee will review safety data following a fifth consecutive dose of Connaught's Tripedia (diphtheria/tetanus/acellular pertussis vaccine). The meeting will be held at the Holiday Inn in Bethesda, Md., beginning at 8 a.m. each day. The committee will meet in closed session from 8-9 a.m. on Nov. 4 and from 1:30-2 p.m. on Nov. 5
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth